#Chronic inflammatory demyelinating polyneuropathy

[redroses07]

The worst part about being chronically ill/ living with a rare disease, is I have to explain that I’m not in class cause I had an episode, fell on the floor, then couldn’t get out of bed.

[cljordan-imperium]

CJ is sick...my immune system has declared war...shots have been fired...steroids are being deployed... wie ein Modder- Igel fühlen

Ich fühl mich wie gematschte Bananen

Ich fühl mich scheiße

And gifts for my German besties for accurate descriptions of how I feel @saltysupercomputer @dreaminggoblin @writingmaidenwarrior

And I'm not contagious, so they're safe

[coffee-n-bagels-comic-universe]

God, what a journey. I have CIDP.

On the 8th of May I was told that my official diagnosis is 'CIDP' (Chronic Inflammatory Demyelinating Polyneuropathy) I have gone from the introverted but all-out goth willing to wear that blue dress into a hospital (first pic) to (with a fresh haircut) the dying to be out of the house, sill goth, geek (last pic)

I say this not to beg for sympathy but to say I'm officially disabled and finally at a comfortable point to say that, I am weird, I am Autistic, and I'm practically wheelchair-bound.

I am a rare case, most CIDP cases aren't in their early 20s with no prior illnesses before this happens to them, but I am lucky enough to live in the UK and have free healthcare, I can complain about wait times in A&E, or the slow way hospitals communicate, but I'm writing this to say that you should look out for yourself, cause you never know what will happen.

[oleander-teacup]

hey cidp gang. my dad was officially diagnosed after suspecting for several years just a few months ago and is having a really hard time with coming to terms with needing a mobility aid.

what would you suggest for easing someone into using a mobility aid? as someone else with autoimmune issues i use braces galore but i dont feel weird about using them because i know they help me to like. literally walk. so i dont exactly know where he's coming from here. any advice?

[springstick]

A Kinda Ramble About Health

Sorry for not posting for a few days. I have been struggling with my immune condition a lot recently. I've been getting really bad tremors in my hands, and loss of motor function, and temporary paralysis in my right hand (probably from overuse / note taking). I have a hard time writing and typing. I'm working on getting appointments set up with my doctors, but it's a week before finals and my neurologist is 2 hours away. Does anyone who has CIDP have any advice?

[disabledsysboxes]

Autoimmune - 4

[does-truth-matter]

The CDC has quietly changed who should AVOID the MMR vaccine.

https://www.cdc.gov/vaccines/vpd/mmr/public/index.html

They now state that ANYONE that “Has a parent, brother or sister with a history of immune system problems” should AVOID THE MMR VACCINE!

What exactly is an 'immune system problem?" Every autoimmune disorder.

* Achalasia

* Addison’s disease

* Adult Still's disease

* Agammaglobulinemia

* Alopecia areata

* Amyloidosis

* Amyotrophic lateral sclerosis (Lou Gehrigs)

* Ankylosing spondylitis

* Anti-GBM/Anti-TBM nephritis

* Antiphospholipid syndrome

* Autoimmune angioedema

* Autoimmune dysautonomia

* Autoimmune encephalomyelitis

* Autoimmune hepatitis

* Autoimmune inner ear disease (AIED)

* Autoimmune myocarditis

* Autoimmune oophoritis

* Autoimmune orchitis

* Autoimmune pancreatitis

* Autoimmune retinopathy

* Autoimmune urticaria

* Axonal & neuronal neuropathy (AMAN)

* Baló disease

* Behcet’s disease

* Benign mucosal pemphigoid

* Bullous pemphigoid

* Castleman disease (CD)

* Celiac disease

* Chagas disease

* Chronic inflammatory demyelinating polyneuropathy (CIDP)

* Chronic recurrent multifocal osteomyelitis (CRMO)

* Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA)

* Cicatricial pemphigoid

* Cogan’s syndrome

* Cold agglutinin disease

* Congenital heart block

* Coxsackie myocarditis

* CREST syndrome

* Crohn’s disease

* Dermatitis herpetiformis

* Dermatomyositis

* Devic’s disease (neuromyelitis optica)

* Discoid lupus

* Dressler’s syndrome

* Endometriosis

* Eosinophilic esophagitis (EoE)

* Eosinophilic fasciitis

* Erythema nodosum

* Essential mixed cryoglobulinemia

* Evans syndrome

* Fibromyalgia

* Fibrosing alveolitis

* Giant cell arteritis (temporal arteritis)

* Giant cell myocarditis

* Glomerulonephritis

* Goodpasture’s syndrome

* Granulomatosis with Polyangiitis

* Graves’ disease

* Guillain-Barre syndrome

* Hashimoto’s thyroiditis

* Hemolytic anemia

* Henoch-Schonlein purpura (HSP)

* Herpes gestationis or pemphigoid gestationis (PG)

* Hidradenitis Suppurativa (HS) (Acne Inversa)

* Hypogammalglobulinemia

* IgA Nephropathy

* IgG4-related sclerosing disease

* Immune thrombocytopenic purpura (ITP)

* Inclusion body myositis (IBM)

* Interstitial cystitis (IC)

* Juvenile arthritis

* Juvenile diabetes (Type 1 diabetes)

* Juvenile myositis (JM)

* Kawasaki disease

* Lambert-Eaton syndrome

* Leukocytoclastic vasculitis

* Lichen planus

* Lichen sclerosus

* Ligneous conjunctivitis

* Linear IgA disease (LAD)

* Lupus

* Lyme disease chronic

* Meniere’s disease

* Microscopic polyangiitis (MPA)

* Mixed connective tissue disease (MCTD)

* Mooren’s ulcer

* Mucha-Habermann disease

* Multifocal Motor Neuropathy (MMN) or MMNCB

* Multiple sclerosis

* Myasthenia gravis

* Myositis

* Narcolepsy

* Neonatal Lupus

* Neuromyelitis optica

* Neutropenia

* Ocular cicatricial pemphigoid

* Optic neuritis

* Palindromic rheumatism (PR)

* PANDAS

* Parkinson's disease

* Paraneoplastic cerebellar degeneration (PCD)

* Paroxysmal nocturnal hemoglobinuria (PNH)

* Parry Romberg syndrome

* Pars planitis (peripheral uveitis)

* Parsonage-Turner syndrome

* Pemphigus

* Peripheral neuropathy

* Perivenous encephalomyelitis

* Pernicious anemia (PA)

* POEMS syndrome

* Polyarteritis nodosa

* Polyglandular syndromes type I, II, III

* Polymyalgia rheumatica

* Polymyositis

* Postmyocardial infarction syndrome

* Postpericardiotomy syndrome

* Primary biliary cirrhosis

* Primary sclerosing cholangitis

* Progesterone dermatitis

* Psoriasis

* Psoriatic arthritis

* Pure red cell aplasia (PRCA)

* Pyoderma gangrenosum

* Raynaud’s phenomenon

* Reactive Arthritis

* Reflex sympathetic dystrophy

* Relapsing polychondritis

* Restless legs syndrome (RLS)

* Retroperitoneal fibrosis

* Rheumatic fever

* Rheumatoid arthritis

* Sarcoidosis

* Schmidt syndrome

* Scleritis

* Scleroderma

* Sjögren’s syndrome

* Sperm & testicular autoimmunity

* Stiff person syndrome (SPS)

* Subacute bacterial endocarditis (SBE)

* Susac’s syndrome

* Sympathetic ophthalmia (SO)

* Takayasu’s arteritis

* Temporal arteritis/Giant cell arteritis

* Thrombocytopenic purpura (TTP)

* Tolosa-Hunt syndrome (THS)

* Transverse myelitis

* Type 1 diabetes

* Ulcerative colitis (UC)

* Undifferentiated connective tissue disease (UCTD)

* Uveitis

* Vasculitis

* Vitiligo

* Vogt-Koyanagi-Harada Disease

Wonder how many doctors are paying attention?

~shared from Jodi Wilson

[shapedforfighting]

What's fucked up is that my nerve disorder pills for the pain in my feet have to be taken with food but when I wake up in the morning my feet hurt enough that I don't want to walk on them into the kitchen to make food to take the feet-pain-fixing pills

[ptmasterguide]

Chronic Inflammatory Demyelinating Polyneuropathy

Progressive muscle weakness and loss of sensation in the extremities characterize CIDP, or Chronic Inflammatory Demyelinating Polyneuropathy, a neurological disorder. An autoimmune condition, CIDP means the body’s immune system mistakenly attacks its own nerves. Key features of CIDP: Progressive muscle weakness: This often begins in the feet and legs but can spread to the hands and arms over…

[newsheadlinesnow]

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Assessment 2024 | Clinical Trials, Latest Approvals, Key Players | Sanofi, Johnson & Johnson, Immunovant, UCB S.A., GeNeuro

http://dlvr.it/TCWlLf

[redroses07]

This probably makes me sound like a brat, but I really wish I had the opportunity to go to the Eras Tour again. Of course I’m so grateful that I even got to go once, but when I went in 2023 I was really struggling with my chronic illness and had to spend the concert in a wheelchair. I had just gotten out of the hospital a week before, so I was still learning how to navigate life with a disability. It was an overall very stressful experience for me. I’m now walking again and can’t help but want to see the show again.

[cljordan-imperium]

This is the first time that the name of a bot has made me legit laugh out loud and HARD. I have an autoimmune condition known as chronic inflammatory demyelinating polyneuropathy - basically my immune system destroys the proteins around my nerves and causes extremely painful peripheral neuropathy. So The idea of an Overpowering Nerve following me?! NOPE! FUCK NOPE! Fuck straight off... *dies laughing*

[conversationpoint]

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Assessment 2024 | Clinical Trials, Latest Approvals, Key Players | Sanofi, Johnson & Johnson, Immunovant, UCB S.A., GeNeuro

http://dlvr.it/TCWk2v

[industryinsightsandanalysis]

The Intravenous Immunoglobulin Market: Trends, Drivers, and Future Prospects

Intravenous immunoglobulin (IVIG) is a critical therapy used to treat a variety of autoimmune, infectious, and idiopathic diseases. Derived from the plasma of thousands of donors, IVIG is composed of a mixture of antibodies that play a crucial role in immune system modulation. The global IVIG market has seen significant growth over the past decade, driven by the increasing prevalence of immunodeficiency diseases and the expanding therapeutic applications of IVIG. This article explores the current state of the IVIG market, its key drivers, challenges, and future outlook.

Market Overview

As of 2023, the global Intravenous immunoglobulin market was valued at approximately USD 13 billion, with projections indicating a robust compound annual growth rate (CAGR) of around 8% over the next five years. The demand for IVIG is on the rise due to its effectiveness in treating a wide range of medical conditions, including primary immunodeficiency diseases (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, and various other autoimmune and inflammatory diseases.

Key Drivers

1. Increasing Prevalence of Immunodeficiency Disorders: The growing incidence of primary and secondary immunodeficiency disorders is a significant driver for the IVIG market. These conditions require regular IVIG therapy to boost the immune system and prevent infections.

2. Expanding Therapeutic Applications: IVIG is increasingly being used off-label for a variety of conditions, including multiple sclerosis, myasthenia gravis, and certain neurological disorders. The expanding list of indications is broadening the market's scope.

3. Advancements in Manufacturing Processes: Technological advancements in the production and purification of immunoglobulins have improved the safety and efficacy of IVIG products. Enhanced manufacturing techniques ensure higher yields and better product consistency.

4. Rising Geriatric Population: The aging global population is more susceptible to immune system dysfunctions and autoimmune diseases, thereby increasing the demand for IVIG therapies. Older adults often require more frequent and higher doses of IVIG to manage their conditions.

5. Government and Organizational Support: Various health organizations and governments are actively supporting the availability and affordability of IVIG. Initiatives to ensure a steady supply of plasma, essential for IVIG production, are also contributing to market growth.

For a comprehensive analysis of the market drivers, visit https://univdatos.com/report/intravenous-immunoglobulin-market/

Challenges

Despite its significant potential, the IVIG market faces several challenges:

1. High Cost of Therapy: IVIG treatment is expensive, which can limit accessibility, especially in low- and middle-income countries. The high cost is attributed to the complex manufacturing process and the need for plasma from multiple donors.

2. Supply Constraints: The production of IVIG relies on the availability of human plasma, which can be subject to fluctuations due to donation rates and regulatory restrictions. This dependency on plasma supply can lead to shortages and impact market stability.

3. Adverse Effects: While IVIG is generally well-tolerated, it can cause side effects such as headaches, fever, and allergic reactions. Severe adverse events, although rare, can also occur, necessitating careful patient monitoring.

4. Regulatory Hurdles: The stringent regulatory environment governing the collection, processing, and distribution of plasma products can pose challenges. Compliance with these regulations is critical to ensure product safety and efficacy but can also delay market entry for new products.

Regional Insights

The IVIG market shows considerable regional variation. North America dominates the market due to high healthcare expenditure, advanced healthcare infrastructure, and a high prevalence of immunodeficiency diseases. Europe follows closely, supported by robust healthcare systems and significant investments in medical research.

The Asia-Pacific region is expected to witness the fastest growth, driven by increasing healthcare awareness, rising disposable incomes, and improving healthcare infrastructure. Countries like China and India are emerging as key markets, with growing demand for advanced medical therapies and increased focus on healthcare improvements.

For a sample report, visit https://univdatos.com/get-a-free-sample-form-php/?product_id=22667

Future Outlook

The future of the IVIG market looks promising, with continued advancements in therapeutic applications and production technologies. Research into novel uses of IVIG and the development of subcutaneous immunoglobulin (SCIG) therapies offer additional growth opportunities. SCIG provides an alternative to IVIG with the convenience of home administration, potentially expanding patient access and adherence.

Furthermore, efforts to increase plasma donations through awareness campaigns and donor incentives are crucial to addressing supply constraints. Collaboration between governments, healthcare providers, and pharmaceutical companies will be essential to ensure a stable and sustainable supply of plasma-derived therapies.

Conclusion

The intravenous immunoglobulin market is poised for significant growth, driven by the increasing prevalence of immunodeficiency diseases, expanding therapeutic indications, and advancements in production technologies. While challenges such as high costs and supply constraints persist, ongoing research and strategic collaborations hold promise for a brighter future. As the demand for effective immunotherapies continues to rise, IVIG will remain a vital component of modern medicine, offering hope and improved quality of life for patients worldwide.

Contact Us:

UnivDatos Market Insights

Email - contact@univdatos.com

Contact Number - +1 9782263411x

Website -www.univdatos.com

[saumayatripathi]

Navigating the Landscape: IVIG Injection Manufacturers and Exporters in India

In the realm of medical advancements, Intravenous Immunoglobulin (IVIG) Injections stand as a pivotal solution for various autoimmune and inflammatory conditions. But what exactly are IVIG Injections, and why are they indispensable in modern healthcare?

Understanding IVIG Injections: A Lifeline in Healthcare IVIG, short for Intravenous Immunoglobulin, refers to a therapy derived from blood plasma containing antibodies. These antibodies play a crucial role in bolstering the immune system, making IVIG Injections a cornerstone in the treatment of autoimmune disorders, immunodeficiencies, and even neurological conditions. By infusing these antibodies directly into the bloodstream, IVIG therapy aims to modulate the immune response, quelling aberrant reactions and restoring equilibrium within the body.

The Role of IVIG Injections: A Multifaceted Approach From chronic inflammatory demyelinating polyneuropathy (CIDP) to Kawasaki disease, IVIG Injections demonstrate versatility in addressing a spectrum of medical conditions. Whether it’s combating immune deficiencies or mitigating the symptoms of autoimmune disorders like lupus or rheumatoid arthritis, IVIG therapy offers relief and hope to countless patients worldwide.

Florencia Healthcare: Spearheading Excellence in IVIG Manufacturing and Export Amidst the landscape of IVIG injection manufacturers and suppliers in India, one name shines brightly – Florencia Healthcare. Renowned for its unwavering commitment to quality and innovation, Florencia Healthcare stands tall as a leading player in the realm of IVIG production and exportation. With state-of-the-art facilities and a team of skilled professionals, Florencia Healthcare ensures that every batch of IVIG Injections meets stringent quality standards, adhering to regulatory guidelines and surpassing expectations.

Navigating the Competitive Terrain: Why Choose Florencia Healthcare? In a market teeming with options, Florencia Healthcare distinguishes itself through a combination of factors. From its adherence to Good Manufacturing Practices (GMP) to its relentless pursuit of excellence in research and development, Florencia Healthcare prioritizes efficacy, safety, and patient well-being above all else. With a global footprint spanning across continents, Florencia Healthcare exemplifies reliability and trustworthiness, earning the confidence of healthcare professionals and patients alike.

Charting the Course Ahead: Embracing Innovation and Excellence As the demand for IVIG therapy continues to rise, the importance of reliable and reputable manufacturers cannot be overstated. In this dynamic landscape, Florencia Healthcare remains steadfast in its mission to deliver cutting-edge solutions and redefine the standards of excellence in IVIG manufacturing and exportation. With an unwavering commitment to quality and a vision for a healthier tomorrow, Florencia Healthcare paves the way forward, navigating the landscape with integrity, innovation, and compassion.

In Conclusion: In the realm of IVIG injection manufacturers and Exporters in India, Florencia Healthcare stands as a beacon of excellence and reliability. With a steadfast commitment to quality, innovation, and patient well-being, Florencia Healthcare continues to redefine the standards of IVIG manufacturing and exportation, charting a course towards a healthier, more vibrant future for all.